MedCognetics

Executive Summary

MedCognetics is a US-based medical AI company founded in 2018 that develops artificial intelligence software for cancer detection, initially focusing on breast cancer screening. The company's platform is designed to assist radiologists by improving workflow efficiency and diagnostic accuracy in mammography, aiming to enable earlier detection and better patient outcomes. As a private company in the AI/ML diagnostics and oncology space, MedCognetics operates in a rapidly growing market with significant competitive pressure from established players like Hologic and ScreenPoint Medical. The company has not disclosed funding rounds or regulatory approvals, suggesting it is still in an early stage of development or pre-revenue. While the technology holds promise, especially given the high rates of false positives and missed cancers in current screening, the lack of public clinical validation or deployment data introduces substantial uncertainty. The company's ability to secure FDA clearance and form partnership with healthcare providers will be critical to its success. Overall, MedCognetics represents an early-stage bet on AI-driven diagnostic improvement, with potential rewards contingent on regulatory and commercial milestones.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for breast cancer detection AI60% success
• Q3 2026Partnership with a major hospital or imaging chain50% success
• Q2 2026Series A funding announcement70% success